On July 20, 2021 OPKO Health, Inc. (NASDAQ: OPK) reported operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, July 29, 2021. OPKO’s senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on July 29th beginning at 4:30 p.m. Eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using the link here. Upon registering, participants will receive dial-in numbers, an event passcode and a unique registrant ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the start of the call. Alternatively, please dial (888) 869-1189 or (706) 643-5902 and use conference ID 7028169

To access the live call via webcast, please click on the link OPKO 2Q21 Results Conference Call. Individual investors and investment community professionals who do not plan to ask a question during the call’s Q&A session are encouraged to listen to the call via the webcast.

For those unable to listen to the live conference call, a replay can be accessed for a period of time on OPKO’s website at OPKO 2Q21 Results Conference Call. A telephone replay will be available beginning approximately two hours after the close of the conference call. To access the replay, please dial (855) 859-2056 or (404) 537-3406, and use conference ID 7028169.

On July 20, 2021 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported the closing of its initial public offering of 21,562,500 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 2,812,500 additional shares, at an initial public offering price of $16.00 per share (Press release, Erasca, JUL 20, 2021, View Source [SID1234639385]). The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Erasca, were $345.0 million. Erasca’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol "ERAS."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, and Guggenheim Securities acted as joint book-running managers for the offering.

Registration statements relating to the offering have been filed with the Securities and Exchange Commission (SEC) and became effective on July 15, 2021. A prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (866) 803-9204, or by email at [email protected]; from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at [email protected]; from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at [email protected]; from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email at [email protected]; or from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On July 20, 2021 ChromaDex Corp. (NASDAQ:CDXC) reported that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021 (Press release, ChromaDex, JUL 20, 2021, View Source [SID1234584964]). The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Conference Call:

ChromaDex management will host an investor conference call to discuss the second quarter results and provide a general business update on Tues., August 3, at 4:30 p.m. ET.

Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:

The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.

On July 20, 2021 Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, reported that it will report financial results for its first fiscal quarter ended June 30, 2021 on Tuesday, August 10, 2021 (Press release, Beyond Air, JUL 20, 2021, View Source [SID1234584981]). The Company’s management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 20, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that it will host a key opinion leader webinar on Tuesday, July 27, 2021, at 8 am Eastern Time (Press release, Infinity Pharmaceuticals, JUL 20, 2021, View Source [SID1234584965]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webinar will provide updates on the MARIO-3 TNBC and MARIO-275 UC clinical studies, both of which add eganelisib to approved standard of care regimens. MARIO-3 is a Phase 2 triplet combination study evaluating the addition of eganelisib to the approved standard of care combination of Tecentriq and Abraxane in the front-line setting in TNBC. MARIO-275 is a randomized, controlled Phase 2 combination study evaluating the addition of eganelisib to the approved standard of care Opdivo monotherapy in the second line setting for immune-oncology naïve UC patients who have progressed on a platinum therapy.

The webinar will feature a presentation by Erika P. Hamilton, M.D. of Sarah Cannon Research Institute at Tennessee Oncolgy, of updated data from MARIO-3 in the context of the current standard of care. Dr. Hamilton presented initial MARIO-3 TNBC data at the 2020 San Antonio Breast Cancer Symposium in December 2020 and will be available to answer questions following the formal presentation.

Brian Schwartz, M.D., Consulting Chief Physician of Infinity, will present a status update on eganelisib in UC that builds upon the initial data from MARIO-275 Phase 2 study in second line patients with UC, which he presented at the 2021 ASCO (Free ASCO Whitepaper) Genitourinary Cancers Symposium in February 2021 and will be available to answer questions following the formal presentation.

To register for the webinar, please click here.

Dr. Hamilton joined Sarah Cannon as investigator, drug development and women’s cancer in 2013. Her responsibilities include overseeing the breast cancer research program as well as caring for patients with breast and gynecologic cancers in the clinic. After receiving an undergraduate degree from Washington and Lee University in Virginia, Dr. Hamilton completed her medical degree and residency from University of North Carolina in Chapel Hill. She received her fellowship training in hematology and oncology from Duke University in Durham, North Carolina, where she was recognized as a Top 5 Finalist for Duke’s Annual House staff Fellow Teaching Award. Dr. Hamilton is board certified in internal medicine and oncology.

Dr. Brian Schwartz has more than a decade of experience as a drug development expert in pharmaceutical and biotechnology industries, spanning several therapeutic areas including oncology, dermatology, neurology and rare diseases. In senior leadership roles at ArQule, Ziopharm, Bayer and Leo Labs, Dr. Schwartz has accumulated a number of successful New Drug Applications (NDA), numerous Investigational New Drug (IND) applications, preclinical and clinical drug development programs. During his time in biotech, Dr. Schwartz acquired knowledge of investors relations, partnering and capital raising. Currently, Dr. Schwartz is an advisor for California Institute of Regenerative Medicine, numerous biotech companies and board member of LifeSci Acquisition Corp. Dr. Schwartz qualified as a medical doctor in South Africa followed by additional fellowship training in Canada.